Serum nesfatin-1 levels are decreased in pregnant women newly diagnosed with gestational diabetes

Abstract

Objective: To investigate serum nesfatin-1 levels at 24-28 weeks of pregnancy in women newly diagnosed with gestational diabetes and determine the association of nesfatin-1 with several metabolic parameters. Subjects and methods: Forty women newly diagnosed with gestational diabetes at 24-28 weeks of pregnancy and 30 healthy pregnant women matched in age and gestational week were included in this cross-sectional study. Serum nesfatin-1 levels were analyzed using ELISA, and the relationship between nesfatin-1 and several metabolic parameters were assessed. Results: Serum nesfatin-1 levels were found to be lower in women with gestational diabetes compared to the pregnant women in the control sample (p = 0.020). Multiple linear regression analysis revealed that nesfatin-1 was lower in participants with gestational diabetes independently from gestational age, BMI, HOMA-IR, fasting plasma glucose, and age. In correlation analysis, the only variable that was found to have a statistically significant correlation with nesfatin-1 was gestational age (p = 0.015, r = 0.30). Conclusion: Lower nesfatin-1 levels in women with gestational diabetes compared to the control group at 24-28 weeks of gestation draws attention to nesfatin-1 levels in gestational diabetes and motivates further research in this area. Arch Endocrinol Metab. 2017;61(5):455-9

Nesfatin-1 and Vaspin as Potential Novel Biomarkers for the Prediction and Early Diagnosis of Gestational Diabetes Mellitus

“…There are only a few studies that have analyzed the serum level of nestafin-1 in pregnant woman with GDM, and the data are not clear [24,25,26,27]. In our study, we observed that in patients with GDM, nesfatin-1 serum concentrations remained significantly lower than in the group of healthy pregnant women (5.15 ± 3.51 vs. 6.69 ± 4.21 ng/mL).…”

Circulating FABP4, nesfatin-1, and osteocalcin concentrations in women with gestational diabetes mellitus: a meta-analysis

“…In the previous researches, the correlation between nesfatin-1 levels and BMI remained unclear [12,37]. The findings from the meta-analysis, manifested that women with GDM and a high BMI displayed substantially lower nesfatin-1 concentrations than women with a normal weight suffering from GDM, which was in line with the negative relationship between nesfatin-1 concentration and BMI.…”

“…Among the 806 articles retrieved, 31 were eligible; 14 were FABP4 studies [ 8 , 17 – 19 , 26 – 36 ], seven were nesfatin-1 studies [ 10 , 12 , 20 , 37 – 40 ], seven were OC studies [ 14 , 21 , 41 – 45 ], and three articles covered both FABP4 and nesfatin-1 [ 11 , 46 , 47 ]. The 31 studies involved 4590 participants; 2059 were GDM patients and 2531 were healthy pregnant women [ 8 , 10 – 12 , 14 , 17 – 21 , 26 – 47 ] (Fig. 1 ).…”

“…Furthermore, nesfatin-1 also performs the critical function of regulating glucose metabolism. Ademoglu et al [12] has shown that nesfatin-1 exerted unique influence on the development of T2DM by stimulating free acid utilization, but its effects on GDM are unknown.…”

Current Understanding of the Role of Nesfatin-1

“…In patients with gestational diabetes mellitus serum NUCB2/nesfatin-1 concentrations, NUCB2/nesfatin-1 levels in cord blood and protein expression of NUCB2/nesfatin-1 in subcutaneous fat were higher than in healthy pregnant subjects [ 106 ]. Inconsistently, a previous [ 107 ] and a subsequent [ 108 ] study showed the opposite regulation, with decreased serum NUCB2/nesfatin-1 levels and a positive association between NUCB2/nesfatin-1 and gestational week [ 108 ]. These discrepant results might be due to, although subtle, differences in age (29.6 ± 5.3 vs .…”